参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Small Cell Lung Cancer Version 1.2019-October 10, 2018.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018.CA Cancer J Clin 2018, 68: 7-30.
4.Rivera MP, Mehta AC, Wahidi MM.Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest 2013, 143: e142S-165S.
5.Travis WD, Brambilla E, Burke AP, et al.Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.J Thorac Oncol 2015, 10: 1240-1242.
6.Rindi G, Klersy C, Inzani F, et al.Grading the neuroendocrine tumors of the lung: an evidence-based proposal.Endocr Relat Cancer 2014, 21: 1-16.
7.Ordonez NG.Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas.Am J Surg Pathol 2000, 24: 1217-1223.
8.Pelosi G, Rindi G, Travis WD, et al.Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.J Thorac Oncol 2014, 9: 273-284.
9.Hatfield LA, Huskamp HA, Lamont EB.Survival and toxicity after cisplatin plus etoposide versus carboplatin plus etoposide for extensive-stage small-cell lung cancer in elderly patients.J Oncol Pract 2016, 12: 666-673.
10.Jalal SI, Lavin P, Lo G, et al.Carboplatin and etoposide with or without palifosfamide inuntreated extensivestage small-cell lung cancer: a multicenter, adaptive, randomized phase III study(MATISSE).J Clin Oncol 2017, 35: 2619-2623.(https://www.daowen.com)
11.Petrioli R, Roviello G, Laera L, et al.Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experience.Clin Lung Cancer 2015, 16: e229-234.
12.Tiseo M, Boni L, Ambrosio F, et al.Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: The GOIRCAIFA FARM6PMFJM trial.J Clin Oncol 2017, 35: 1281-1287.
13.Reck M, Luft A, Szczesna A, et al.Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer.J Clin Oncol 2016, 34: 3740-3748.
14.Gridelli C, Casaluce F, Sgambato A, et al.Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs.sequential chemoradiotherapy vs.concurrent chemoradiotherapy: that’s the question.Transl Lung Cancer Res 2016, 5: 150-154.
15.Horn L, Reck M, Spigel DR.The future of immunotherapy in the treatment of small cell lung cancer.Oncologist 2016, 21: 910-921.
16.Hellmann MD, Ott PA, Zugazagoitia J, et al.Nivolumab(nivo)±ipilimumab(ipi)in advanced smallcell lung cancer(SCLC): First report of a randomized expansion cohort from CheckMate 032 [abstract].J Clin Oncol 2017, 35: Abstract 8503.
17.Davies M, Duffield EA.Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.Immunotargets Ther 2017, 6: 51-71.
18.Zauderer MG, Drilon A, Kadota K, et al.Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.Lung Cancer 2014, 86: 237-240.
19.De Ruysscher D, Lueza B, Le Pechoux C, et al.Impact of thoracic radiotherapy timing in limited-stage smallcell lung cancer: usefulness of the individual patient data meta-analysis.Ann Oncol 2016, 27: 1818-1828.
20.Faivre-Finn C, Snee M, Ashcroft L, et al.Concurrent oncedaily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer(CONVERT): an openlabel, phase 3, randomised, superiority trial.Lancet Oncol 2017, 18: 1116-1125.